Lupus anticoagulant (LAC) may serve as a potential biomarker of cardiac dysfunction in patients with systemic lupus erythematosus (SLE), according to study findings published in the Journal of ...

Lupus anticoagulant was the most prevalent (20.6%) followed by aCL IgG (15.8%. One hundred sixteen patients (7.37%), of whom 92 were aPL positive, developed atherosclerotic cardiovascular disease ...

Persistent positivity for lupus anticoagulant appeared particularly important, with a hazard ratio of 12.99 (95% CI 3.07-55.0).